Fibrocell Science Inc

Fibrocell Science — Investor Presentation (March 2018)

21 slides from Fibrocell Science's investor presentation, Mar 19, 2018

  1. Slide 1: Corporate Presentation March 19, 2018

    Corporate Presentation March 19, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward- looking statements for this p

  3. Slide 3: Investment Highlights

    Investment Highlights 3 •Medical breakthroughs for rare diseases of the skin and connective tissue • Unmet needs with no approved therapies • Significant mortality and morbidity impact on pediatric populations Focus on Rare Skin Diseases • Autologous fibroblasts derived from skin are the vehicle to

  4. Slide 4: Development Pipeline

    Development Pipeline 4 Program Condition Target Research Pre-Clinical Phase 1/2 Clinical Trials FDA Designations FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) Type VII Collagen FCX-013 Moderate to Severe Localized Scleroderma MMP-1 Research Arthritis and Related Conditions TBD Orphan Dru

  5. Slide 5: Our Proprietary Fibroblast Platform

    5 Our Proprietary Fibroblast Platform Vector FCX-007 autologous dermal fibroblasts in culture Lentiviral vector gene transfer • 3rd generation and self- inactivating • Accommodates large gene constructs • Transduces both dividing and non- dividing cells • Target gene integration for long- term expre

  6. Slide 6: Personalized Biologics Approach

    Personalized Biologics Approach 6

  7. Slide 7: FCX-007 – Recessive Dystrophic Epidermolysis Bullosa

    FCX-007 – Recessive Dystrophic Epidermolysis Bullosa FCX-007 is a dermal fibroblast transduced with a lentiviral vector encoded with the gene for type VII collagen Orphan Drug Designation Rare Pediatric Disease Designation Fast Track Designation 7

  8. Slide 8: About RDEB

    About RDEB 8 Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a monogenic disease resulting in chronic skin blistering and wounding Photo credit: Science Photo Library Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive,

  9. Slide 9: FCX-007 Phase 1/2 Clinical Trial Design

    FCX-007 Phase 1/2 Clinical Trial Design 9 A Phase 1/2 Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT02810951 Title To evaluate the safety of a single intradermal injection session of FCX-007Primary Objective To ev

  10. Slide 10: FCX-007 Interim Data Readout

    FCX-007 Interim Data Readout • Interim readout of data for three NC1+ adult Phase 1 patients, 12 weeks post- administration • Single injection session of FCX-007 to target wounds or preliminary safety assessment • Five wounds treated over three patients ranging from 4.4cm2 to 13.1cm2 in size • FCX-0

  11. Slide 11: FCX-007 Interim Readout: Wound Healing

    FCX-007 Interim Readout: Wound Healing • Digital images captured and tracings performed  Skin tattoos and transparent overlays used as landmarks • Wounds monitored in the study prior to dosing were open at each monitoring visit up to 8 months • A matched size untreated wound for each treated wound

  12. Slide 12: FCX-007 Interim Readout: Pharmacology

    FCX-007 Interim Readout: Pharmacology 12Texas Red – C7/fNC1 + DAPI + FITC – laminin 332Texas Red – C7/fNC1 • Variable pharmacology signals detected throughout the data set in each patient for one or more assays through 12 weeks post-administration (qPCR, electron microscopy, immunofluorescence)  An

  13. Slide 13: FCX-013 – Moderate to Severe Localized Scleroderma

    FCX-013 – Moderate to Severe Localized Scleroderma FCX-007 is a dermal fibroblast transduced with a lentiviral vector encoded with the gene for MMP-1, under control of the RheoSwitch Therapeutic System® (RTS®) Orphan Drug Designation Rare Pediatric Disease Designation 13

  14. Slide 14: About Localized Scleroderma

    About Localized Scleroderma 14 Disease Epidemiology • Excess production of collagen characterized by skin fibrosis • Focus on moderate to severe subtypes • Thickening may extend to underlying tissue and muscle in children which may impair growth in affected limbs or forehead • Lesions appearing acro

  15. Slide 15: FCX-013 Moving into Clinical Trials

    FCX-013 Moving into Clinical Trials 15 • Product profile  Dermal fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen  Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to control protein

  16. Slide 16: FCX-013 Phase 1/2 Clinical Trial Design

    FCX-013 Phase 1/2 Clinical Trial Design 16 A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Human Dermal Fibroblasts) plus Veledimex for the Treatment of Moderate to Severe Scleroderma (Morphea) Title To evaluate the safety of a single intradermal injection session of FCX-013Prima

  17. Slide 17: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 17 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  18. Slide 18: Manufacturing Experience and Solutions

    Fibrocell’s existing cGMP cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 and FCX-013 • ~13,000 square foot facility includes:  Cleanroom for cell culture manufacturing  On-site quality control testing laboratories  Cryogenic storage Wareho

  19. Slide 19: Anticipated Milestones 2018-2019

    2Q2018 Interim Phase 1 data readout and trial update Dose first Phase 2 patient FCX-007 Anticipated Milestones 2018-2019 January 2018 FDA allowance of pediatric patient enrollment in Phase 2 March 2018 FDA allowance of IND 3Q2018 Complete enrollment of Phase 2 patients 3Q2018 Initiate enrollment of

  20. Slide 20: Investment Highlights

    Investment Highlights 20 •Medical breakthroughs for rare diseases of the skin and connective tissue • Unmet needs with no approved therapies • Significant mortality and morbidity impact on pediatric populations Focus on Rare Skin Diseases • Autologous fibroblasts derived from skin are the vehicle to

  21. Slide 21: References

    References 1 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA)

Fibrocell Science — Investor Presentation (March 2018) on 6ix